Role of Cerebral Blood Flow on Ventilatory Stability During Sleep in Normoxia and Intermittent Hypoxia
Overview
- Phase
- Phase 1
- Intervention
- Drug Lowering Cerebral Blood Flow (CBF) and Normoxia Sleep
- Conditions
- Obstructive Sleep Apnea of Adult
- Sponsor
- University of Calgary
- Enrollment
- 12
- Primary Endpoint
- Changes in cerebral blood flow and ventilatory chemoreflexes
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
A prospective double blind, placebo-controlled, randomized cross-over trial to evaluate the effect of lowering cerebral blood flow on the ventilatory chemoreflexes (acute hypoxic and hypercapnic ventilatory responses).
Detailed Description
The investigators will explore the relationship between changes in Cerebral Blood Flow (CBF) and ventilatory chemoreflexes i.e. Acute Ventilatory Response to Hypoxia (AHVR) and Acute Hypercapnic Ventilatory Response (HCVR) before, during and after sleep under normoxic conditions and sleep accompanied by isocapnic Intermittent Hypoxia (IH) among healthy human study participants. A pharmacological intervention will be utilized to manipulate the CBF in a randomized order. The study participants will also be randomly assigned the order to sleep either under normoxia or IH exposure. The experiments will be separated from one another with an interval of sufficient drug and IH exposure washout period. The venous blood samples and urinary samples will be collected for the vascular biomarkers.
Investigators
Marc Poulin
PhD, DPhil, Professor
University of Calgary
Eligibility Criteria
Inclusion Criteria
- •Healthy adults
- •18 - 45 years of age
- •Living in Calgary for the past one year
- •Have no medical condition or should not be taking any blood pressure medications.
- •The participant should not be lactose intolerant
Exclusion Criteria
- •Cerebrovascular, cardio-respiratory, renal and metabolic diseases
- •Bleeding disorders and upper gastrointestinal diseases e.g. peptic ulcer disease
- •Pregnancy, obese and sleep-disordered breathing
- •Drug allergies to non-steroidal anti-inflammatories
- •Currently smoking
Arms & Interventions
CBF Lowering and Normoxia Sleep
Study participants will take drug lowering Cerebral Blood Flow (CBF) and sleep under room air i.e. normoxia exposure.
Intervention: Drug Lowering Cerebral Blood Flow (CBF) and Normoxia Sleep
CBF Lowering and IH Sleep
Study participants will take drug lowering Cerebral Blood Flow (CBF) and sleep under Intermittent Hypoxia (IH) exposure.
Intervention: Drug Lowering CBF and Intermittent Hypoxia Sleep
Placebo and Normoxia Sleep
Study participants will take Placebo that has no effect on Cerebral Blood Flow (CBF) and sleep under room air i.e. normoxia exposure.
Intervention: Placebo and Normoxia Sleep
Placebo and IH Sleep
Study participants will take Placebo that has no effect on Cerebral Blood Flow (CBF) and sleep under Intermittent Hypoxia (IH) exposure.
Intervention: Placebo and Intermittent Hypoxia Sleep
Outcomes
Primary Outcomes
Changes in cerebral blood flow and ventilatory chemoreflexes
Time Frame: ~18 months (from the starting time of recruiting study participants)
The relationship between changes in cerebral blood flow (CBF) and ventilatory chemoreflexes (acute hypoxic and hypercapnic ventilatory responses) before and after sleeping under normoxia and intermittent hypoxia exposure among healthy human study participants.
Cerebral blood flow responses and ventilatory chemoreflexes during sleep
Time Frame: ~18 months (from the starting time of recruiting study participants)
The relationship between cerebral blood flow (CBF) changes and ventilatory chemoreflexes (acute hypoxic and hypercapnic ventilatory responses) during sleep under normoxia and intermittent hypoxia exposure among healthy human study participants.
Secondary Outcomes
- Changes in reactive oxygen species and vascular biomarkers(~24 months (from the starting time of recruiting study participants))